Announced details
A clinical-grade UDC line (clinical strain) was completed in 2020. Since then, UDC has been provided to research institutions and companies worldwide, and its applicability is being evaluated.
Registration number: ZL202180037981.5; application number: 202180037981.5; expiry date: Not disclosed
No impact on consolidated results for the fiscal year ending December 2026
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Helios UDC (Universal Donor Cell) |
| Applicable area | Development of regenerative medicine products, Raw materials for cell-based pharmaceuticals, Treatment of various diseases |
| Registration number and expiry date | Registration number: ZL202180037981.5; application number: 202180037981.5; expiry date: Not disclosed |
| Usage history | A clinical-grade UDC line (clinical strain) was completed in 2020. Since then, UDC has been provided to research institutions and companies worldwide, and its applicability is being evaluated. |
| Impact on Business Performance | No impact on consolidated results for the fiscal year ending December 2026 |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The patent was registered in China. The company states that the grant of this patent formally recognizes the technology's originality and novelty outside Japan and strengthens its competitiveness in Japan and overseas.